Showing results (1971-1980 of 2,232) with videos related to
Sort By:
Pageof 224
BMJ Oncology|February 25, 2026
SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancerQing Zhou, Bo Gao, Jie Hu, et al.Nature Medicine|March 28, 2026
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trialByoung Chul Cho, Rama Balaraman, Hua-Jun Chen, et al.Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastasesKai Yin, Yang-Si Li, Mei-Mei Zheng, et al.Clinical Lung Cancer|May 5, 2010
Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma componentWen-Zhao Zhong, Yi-Long Wu, Xue-Ning Yang, et al.Oncotarget|June 5, 2016
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancerLan-Ying Gou, An-Na Li, Jin-Ji Yang, et al.Nature Communications|August 1, 2019
A high-speed search engine pLink 2 with systematic evaluation for proteome-scale identification of cross-linked peptidesZhen-Lin Chen, Jia-Ming Meng, Yong Cao, et al.Clinical Lung Cancer|December 25, 2024
PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System DiseaseChang Lu, Hong-Hong Yan, Chan-Yuan Zhang, et al.Lung Cancer (Auckland, N.Z.)|May 14, 2026
Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung CancerSi-Yang Maggie Liu, Zhi Xie, Lixu Yan, et al.Analytical Chemistry|November 14, 2023
Tumor Microenvironment-Responsive One-for-All Molecular-Engineered Nanoplatform Enables NIR-II Fluorescence Imaging-Guided Combinational Cancer TherapyGui-Long Wu, Fen Liu, Na Li, et al.Ebiomedicine|September 14, 2020
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinomaHao Sun, Si-Yang Liu, Jia-Ying Zhou, et al.Pageof 224